SG10201701057SA - Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione - Google Patents

Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Info

Publication number: SG10201701057SA
Authority: SG; Singapore
Prior art keywords: oxoisoindolin; morpholinomethyl; dione; piperidine; oxy
Prior art date: 2012-08-09

Application number

SG10201701057SA

Inventor

Peter H Schafer

Anita Gandhi

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-08-09

Filing date

2013-08-08

Publication date

2017-03-30

2013-08-08 Application filed by Celgene Corp filed Critical Celgene Corp

2017-03-30 Publication of SG10201701057SA publication Critical patent/SG10201701057SA/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

SG10201701057SA 2012-08-09 2013-08-08 Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione SG10201701057SA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261681447P	2012-08-09	2012-08-09
US201261722727P	2012-11-05	2012-11-05

Publications (1)

Publication Number	Publication Date
SG10201701057SA true SG10201701057SA (en)	2017-03-30

Family

ID=49004013

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG11201500998QA SG11201500998QA (en)	2012-08-09	2013-08-08	Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
SG10201701057SA SG10201701057SA (en)	2012-08-09	2013-08-08	Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
SG10202108516PA SG10202108516PA (en)	2012-08-09	2013-08-08	Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG11201500998QA SG11201500998QA (en)	2012-08-09	2013-08-08	Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10202108516PA SG10202108516PA (en)	2012-08-09	2013-08-08	Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Country Status (31)

Country	Link
US (3)	US20140045843A1 (en)
EP (2)	EP3949968A1 (en)
JP (2)	JP6347782B2 (en)
KR (3)	KR102266510B1 (en)
CN (4)	CN108245518B (en)
AU (1)	AU2013299627C1 (en)
BR (1)	BR112015002285B1 (en)
CA (1)	CA2881116C (en)
CY (1)	CY1124622T1 (en)
DK (1)	DK2882442T3 (en)
EA (1)	EA029485B1 (en)
ES (1)	ES2881220T3 (en)
HK (1)	HK1211489A1 (en)
HR (1)	HRP20211243T1 (en)
HU (1)	HUE056127T2 (en)
IL (3)	IL288506B2 (en)
IN (1)	IN2015DN00886A (en)
LT (1)	LT2882442T (en)
MX (1)	MX367869B (en)
NI (1)	NI201500012A (en)
NZ (1)	NZ628078A (en)
PH (1)	PH12015500212A1 (en)
PL (1)	PL2882442T3 (en)
PT (1)	PT2882442T (en)
RS (1)	RS62201B1 (en)
SG (3)	SG11201500998QA (en)
SI (1)	SI2882442T1 (en)
TW (2)	TWI723266B (en)
UA (1)	UA116544C2 (en)
WO (1)	WO2014025960A1 (en)
ZA (1)	ZA201500564B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010137547A1 (en)	2009-05-25	2010-12-02	国立大学法人東京工業大学	Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells
US8491927B2 (en) *	2009-12-02	2013-07-23	Nimble Epitech, Llc	Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
RS58523B1 (en)	2010-02-11	2019-04-30	Celgene Corp	Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2012135160A1 (en)	2011-03-28	2012-10-04	Pathway Therapeutics Inc.	(alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
WO2014004990A2 (en)	2012-06-29	2014-01-03	Celgene Corporation	Methods for determining drug efficacy using cereblon-associated proteins
US9587281B2 (en)	2012-08-14	2017-03-07	Celgene Corporation	Cereblon isoforms and their use as biomarkers for therapeutic treatment
KR20150054962A (en)	2012-09-10	2015-05-20	셀진 코포레이션	Methods for the treatment of locally advanced breast cancer
US9695145B2 (en)	2013-01-22	2017-07-04	Celgene Corporation	Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
EP3077548B1 (en) *	2013-12-06	2021-11-10	Celgene Corporation	Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
JP6640126B2 (en)	2014-06-27	2020-02-05	セルジーンコーポレイション	Compositions and methods for inducing conformational changes of cerebrons and other E3 ubiquitin ligases
US20180267043A1 (en) *	2014-10-07	2018-09-20	Celgene Corporation	Use of biomarkers for predicting clinical sensitivity to cancer treatment
EP3352756A1 (en) *	2015-09-25	2018-08-01	Celgene Corporation	Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs
WO2017117118A1 (en)	2015-12-28	2017-07-06	Celgene Corporation	Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
KR102002581B1 (en) *	2016-10-04	2019-07-22	주식회사 종근당	Pharmaceutical combinations of histone deacetylase inhibitor and proteasome inhibitor or immunomodulatory drug for the treatment of hematological cancer
US20180238886A1 (en) *	2017-01-31	2018-08-23	Celgene Corporation	Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds
WO2018213302A1 (en) *	2017-05-16	2018-11-22	Biomed Valley Discoveries, Inc.	Compositions and methods for treating cancer with atypical braf mutations
MX2019013862A (en)	2017-05-23	2020-01-20	Mei Pharma Inc	Combination therapy.
EP4201399A3 (en) *	2017-06-30	2023-08-09	Celgene Corporation	Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
JP7258009B2 (en) *	2017-07-10	2023-04-14	セルジーンコーポレイション	Antiproliferative compounds and methods of use thereof
CA3072476A1 (en)	2017-08-14	2019-02-21	Mei Pharma, Inc.	Combination therapy
EP3684366A4 (en) *	2017-09-22	2021-09-08	Kymera Therapeutics, Inc.	Crbn ligands and uses thereof
US11709164B2 (en)	2017-10-26	2023-07-25	National University Of Singapore	Approach for universal monitoring of minimal residual disease in acute myeloid leukemia
EP3737675A4 (en)	2018-01-12	2022-01-05	Kymera Therapeutics, Inc.	Crbn ligands and uses thereof
US11292792B2 (en)	2018-07-06	2022-04-05	Kymera Therapeutics, Inc.	Tricyclic CRBN ligands and uses thereof
MA53237A (en) *	2018-08-14	2021-06-23	Mei Pharma Inc	TREATMENT OF RECURRING FOLLICULAR LYMPHOMA
KR102605291B1 (en) *	2018-09-07	2023-11-23	메드샤인 디스커버리 아이엔씨.	Piperidione compounds substituted by tricyclic furan
SG11202103141YA (en) *	2018-10-01	2021-04-29	Celgene Corp	Combination therapy for the treatment of cancer
BR112021010484A2 (en)	2018-11-30	2021-08-24	Kymera Therapeutics, Inc.	Irak degraders and their uses
AR119715A1 (en) *	2019-04-12	2022-01-05	Celgene Corp	METHODS TO TREAT NON-HODGKIN'S LYMPHOMA WITH THE USE OF 2-(2,6-DIOXOPIPERIDIN-3-IL)-4-((2-FLUORO-4-((3-MORFOLINOAZETIDIN-1-IL)METHYL)BENZYL)AMINO) ISOINDOLIN-1,3-DIONE
EA039874B1 (en) *	2019-06-06	2022-03-22	Общество С Ограниченной Ответственностью "Технология Лекарств"	Composition of pomalidomide for treatment of diseases associated with tumor necrosis factor (tnf)
JP2022554353A (en)	2019-11-07	2022-12-28	ジュノーセラピューティクスインコーポレイテッド	T cell therapy and (S)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-piperidine-2,6- Combination with Dione
AU2020396866A1 (en)	2019-12-02	2022-06-23	Celgene Corporation	Therapy for the treatment of cancer
IL294150A (en)	2019-12-23	2022-08-01	Kymera Therapeutics Inc	Smarca degraders and uses thereof
EP4121043A1 (en)	2020-03-19	2023-01-25	Kymera Therapeutics, Inc.	Mdm2 degraders and uses thereof
TW202210483A (en)	2020-06-03	2022-03-16	美商凱麥拉醫療公司	Crystalline forms of irak degraders
CN115916191A (en) *	2020-06-25	2023-04-04	新基公司	Methods of treating cancer with combination therapy
WO2024015618A2 (en) *	2022-07-15	2024-01-18	St. Jude Children's Research Hospital, Inc.	Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione/2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione analogs as modulators of cereblon protein
WO2024064646A1 (en)	2022-09-20	2024-03-28	Celgene Corporation	Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US5391485A (en)	1985-08-06	1995-02-21	Immunex Corporation	DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (en)	1985-08-23	1988-03-10	麒麟麦酒株式会社	DNA encoding multipotent granulocyte colony stimulating factor
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en)	1989-03-22	1991-07-25	Bioresearch Spa	USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
KR0166088B1 (en)	1990-01-23	1999-01-15	.	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en)	1992-12-24	1994-11-01	The Whitaker Corporation	Wire retainer for current mode coupler
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (en)	1994-07-07	1997-05-07	Recordati Chem Pharm	CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
JP2004526419A (en)	2000-10-16	2004-09-02	フィロスインク．	Protein scaffolds for antibody mimics and other binding proteins
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
WO2002088171A2 (en)	2001-04-26	2002-11-07	Avidia Research Institute	Combinatorial libraries of monomer domains
US7498171B2 (en)	2002-04-12	2009-03-03	Anthrogenesis Corporation	Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7968569B2 (en)	2002-05-17	2011-06-28	Celgene Corporation	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en)	2002-05-17	2008-07-01	Celgene Corporation	Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
MX2007005884A (en)	2004-11-16	2008-02-12	Amgen Mountain View Inc	Protein scaffolds and uses thereof.
US20080051379A1 (en)	2004-12-01	2008-02-28	Trustees Of Boston University	Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms
AR065810A1 (en) *	2007-03-20	2009-07-01	Celgene Corp	DERIVATIVES OF ISOINDOLIN 4'-O-SUBSTITUTES, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND USES THEMSELVES IN THE TREATMENT OF CANCER AND IN OTHER DISORDERS WHERE THE CONTROL OF ANGIOGENESIS OR THE INHIBITION OF CYTOQUINES, INCLUDING TNF-NUTS, INCLUDES.
WO2010137547A1 (en)	2009-05-25	2010-12-02	国立大学法人東京工業大学	Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells
RS58523B1 (en) *	2010-02-11	2019-04-30	Celgene Corp	Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
AU2011224166B2 (en) *	2010-03-12	2014-08-21	Celgene Corporation	Methods for the treatment of non-Hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
CA2829592A1 (en) *	2011-03-11	2012-09-20	Celgene Corporation	Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione

2013
- 2013-08-08 CN CN201711401933.1A patent/CN108245518B/en active Active
- 2013-08-08 DK DK13751007.9T patent/DK2882442T3/en active
- 2013-08-08 HU HUE13751007A patent/HUE056127T2/en unknown
- 2013-08-08 BR BR112015002285-5A patent/BR112015002285B1/en active IP Right Grant
- 2013-08-08 TW TW107117959A patent/TWI723266B/en active
- 2013-08-08 CN CN202110936758.6A patent/CN114366746A/en active Pending
- 2013-08-08 SI SI201331908T patent/SI2882442T1/en unknown
- 2013-08-08 EP EP21177385.8A patent/EP3949968A1/en active Pending
- 2013-08-08 MX MX2015001775A patent/MX367869B/en active IP Right Grant
- 2013-08-08 SG SG11201500998QA patent/SG11201500998QA/en unknown
- 2013-08-08 CN CN201380052496.0A patent/CN104837491A/en active Pending
- 2013-08-08 AU AU2013299627A patent/AU2013299627C1/en active Active
- 2013-08-08 WO PCT/US2013/054055 patent/WO2014025960A1/en active Application Filing
- 2013-08-08 PT PT137510079T patent/PT2882442T/en unknown
- 2013-08-08 IL IL288506A patent/IL288506B2/en unknown
- 2013-08-08 PL PL13751007T patent/PL2882442T3/en unknown
- 2013-08-08 LT LTEPPCT/US2013/054055T patent/LT2882442T/en unknown
- 2013-08-08 SG SG10201701057SA patent/SG10201701057SA/en unknown
- 2013-08-08 UA UAA201501971A patent/UA116544C2/en unknown
- 2013-08-08 CN CN202110938460.9A patent/CN114344307A/en active Pending
- 2013-08-08 JP JP2015526690A patent/JP6347782B2/en active Active
- 2013-08-08 KR KR1020207023283A patent/KR102266510B1/en active IP Right Grant
- 2013-08-08 EA EA201590345A patent/EA029485B1/en not_active IP Right Cessation
- 2013-08-08 IN IN886DEN2015 patent/IN2015DN00886A/en unknown
- 2013-08-08 SG SG10202108516PA patent/SG10202108516PA/en unknown
- 2013-08-08 US US13/962,776 patent/US20140045843A1/en not_active Abandoned
- 2013-08-08 CA CA2881116A patent/CA2881116C/en active Active
- 2013-08-08 RS RS20210904A patent/RS62201B1/en unknown
- 2013-08-08 KR KR1020157006019A patent/KR102146848B1/en active Application Filing
- 2013-08-08 NZ NZ628078A patent/NZ628078A/en unknown
- 2013-08-08 TW TW102128576A patent/TWI653977B/en active
- 2013-08-08 ES ES13751007T patent/ES2881220T3/en active Active
- 2013-08-08 EP EP13751007.9A patent/EP2882442B1/en active Active
- 2013-08-08 KR KR1020217018115A patent/KR102414005B1/en active IP Right Grant
2015
- 2015-01-26 ZA ZA2015/00564A patent/ZA201500564B/en unknown
- 2015-01-29 IL IL237013A patent/IL237013B/en active IP Right Grant
- 2015-01-30 PH PH12015500212A patent/PH12015500212A1/en unknown
- 2015-02-06 NI NI201500012A patent/NI201500012A/en unknown
- 2015-12-17 HK HK15112438.8A patent/HK1211489A1/en unknown
2016
- 2016-05-13 US US15/154,838 patent/US20160256468A1/en not_active Abandoned
2018
- 2018-02-02 JP JP2018017168A patent/JP2018100276A/en not_active Withdrawn
2019
- 2019-08-01 US US16/529,233 patent/US20190388429A1/en active Pending
2020
- 2020-07-27 IL IL276319A patent/IL276319B/en unknown
2021
- 2021-07-16 CY CY20211100645T patent/CY1124622T1/en unknown
- 2021-08-03 HR HRP20211243TT patent/HRP20211243T1/en unknown

Also Published As

Publication number	Publication date
RS62201B1 (en)	2021-08-31
KR102146848B1 (en)	2020-08-21
WO2014025960A1 (en)	2014-02-13
IL288506B1 (en)	2023-05-01
KR102414005B1 (en)	2022-06-27
HRP20211243T1 (en)	2021-11-12
TW201828944A (en)	2018-08-16
EP2882442B1 (en)	2021-06-09
CN114344307A (en)	2022-04-15
TW201434466A (en)	2014-09-16
US20140045843A1 (en)	2014-02-13
AU2013299627C1 (en)	2018-05-31
BR112015002285A2 (en)	2017-07-04
IL288506A (en)	2022-01-01
IL276319A (en)	2020-09-30
HUE056127T2 (en)	2022-01-28
AU2013299627B2 (en)	2018-02-15
IL288506B2 (en)	2023-09-01
ZA201500564B (en)	2016-06-29
NZ628078A (en)	2017-01-27
SI2882442T1 (en)	2021-11-30
IL237013A0 (en)	2015-03-31
MX2015001775A (en)	2015-05-12
MX367869B (en)	2019-09-10
EP2882442A1 (en)	2015-06-17
JP2015524478A (en)	2015-08-24
KR20210073617A (en)	2021-06-18
SG10202108516PA (en)	2021-09-29
PL2882442T3 (en)	2021-12-13
PH12015500212A1 (en)	2015-03-30
PT2882442T (en)	2021-08-17
US20190388429A1 (en)	2019-12-26
LT2882442T (en)	2021-09-27
AU2013299627A1 (en)	2015-02-05
NI201500012A (en)	2019-05-10
JP2018100276A (en)	2018-06-28
CN108245518A (en)	2018-07-06
CN108245518B (en)	2021-08-31
TWI653977B (en)	2019-03-21
SG11201500998QA (en)	2015-04-29
KR20200098730A (en)	2020-08-20
CY1124622T1 (en)	2022-07-22
BR112015002285B1 (en)	2022-05-10
CN114366746A (en)	2022-04-19
KR20150039850A (en)	2015-04-13
US20160256468A1 (en)	2016-09-08
JP6347782B2 (en)	2018-06-27
EA029485B1 (en)	2018-04-30
IL276319B (en)	2022-01-01
HK1211489A1 (en)	2016-05-27
CA2881116A1 (en)	2014-02-13
ES2881220T3 (en)	2021-11-29
EP3949968A1 (en)	2022-02-09
TWI723266B (en)	2021-04-01
UA116544C2 (en)	2018-04-10
DK2882442T3 (en)	2021-08-16
CA2881116C (en)	2021-07-20
IL237013B (en)	2020-08-31
EA201590345A1 (en)	2015-06-30
IN2015DN00886A (en)	2015-06-12
KR102266510B1 (en)	2021-06-16
CN104837491A (en)	2015-08-12

Publication	Publication Date	Title
IL288506A (en)	2022-01-01	Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
HK1191858A1 (en)	2014-08-08	Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3- yl)-piperidine-2,6-dione 3-(5--2--4--4h--3-)--26-
HRP20190398T1 (en)	2019-05-17	A solid form of (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride
IL244494B (en)	2020-05-31	Formulations of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
IL236925A0 (en)	2015-03-31	Processes for the preparation of (s)-3-4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof